Keyword: relapsing-remitting form of multiple sclerosis
News
02.12.2014
- In a late-stage study involving 970 people with primary-progressive multiple sclerosis (PPMS), the Novartis drug Gilenya (fingolimod) failed to show any significant advantages over...